

DAY 1. MORNING, NOVEMBER 17, THURSDAY

8:00-8:30	REGISTRATION	
8:30-8:40	<i>Institutional inauguration by Madrid Health Authority (SERMAS)</i>	
8:40-9:00	<i>OPENING SESSION: Relevance of translational research and future perspectives in the critically illness</i>	Marco Ranieri
9:00-11:00	SESSION 1:	Moderator: Óscar Peñuelas
09:00-09:15	Effects of automation of ventilation on MP in patients with ARDS.	Laura Buiteman-Kruizinga
09:15-09:30	How COVID-19 changed our understanding of respiratory failure.	Lorenzo Ball
09:30-09:45	Does spontaneous breathing activity during mechanical ventilation worsen lung injury?	Marcelo Gama de Abreu
09:45-10:00	Therapy with extracellular vesicles and mitochondria derived from mesenchymal stromal cells in experimental sepsis.	Fernanda F. Cruz
10:00-10:15	Exvivo lung perfusion and translational research.	Lucas Hoyos
10:15-10:40	<i>Discussion.</i>	
10:40-11:00	COFFEE BREAK	
11:00-15:00	SESSION 2:	Moderator: John Laffey
11:00-11:15	Mesenchymal stromal cells for traumatic brain injury. From experimental to clinical studies.	Elisa Zanier
11:15-11:30	Role of plasma extracellular vesicles as organ failure mediators in patients with ARDS.	Vito Fanelli
11:30-11:45	Cell nucleus as a driver of lung injury.	Paula Martín Vicente
11:45-12:00	Mechanical ventilation with low PEEP ventilation Increases mechanical power and pulmonary neutrophilic inflammation in an experimental model of moderate to severe acute lung injury.	Martin Scharffenberg
12:00-12:15	The microRNA signature of ventilator-induced alveolar damage in rats.	Gema Sánchez
12:15-12:30	Insights of the effects of Nitric Oxide in patients on mechanical ventilation.	Fernando Suarez Sipmann
12:30-12:45	Mediation and moderation of imatinib treatment in COVID-19.	Lieuwe Bos
12:45-13:00	Stem Cell Therapy in ARDS and COVID-19.	Patricia Rocco
13:00-13:15	Ex vivo Hypothermic oxygenated perfusion for liver grafts in liver transplantation.	Alberto Pueyo Rabanal
13:15-13:40	<i>Discussion.</i>	
13:40-15:00	LUNCH	

DAY 1. AFTERNOON, NOVEMBER 17, THURSDAY

15:00-17:30	SESSION 3:	Moderator: Nicole Juffermans
15:00-15:15	microRNA-based biomarkers for the clinical management of ARDS secondary to SARS-CoV-2 infection.	David de Gonzalo-Calvo
15:15-15:30	Transcriptomic signatures to guide therapy in ARDS.	Laura Amado-Rodríguez
15:30-15:45	The role of ADAMTS13 in trauma-induced coagulopathy.	Pieter Sloos
15:45-16:00	Traumatic brain injury in patients results in tau pathology displaying prion-like properties in propagation and transmission.	Gloria Vegliante
16:00-16:15	Neurological manifestations in COVID-19 are associated with elevated markers of blood-brain barrier disruption.	Ilaria Lisi
16:15-16:30	<i>Discussion.</i>	
17:00-17:30	COFFEE BREAK	
17:30-18:30	SESSION 4:	Moderator: Guillermo M. Albaiceta
17:15-17:30	LPS induced cardiomyopathy in a mice model.	Vito Fanelli
17:30-17:45	New challenges in the interpretation of lung perfusion-ventilation matching.	Lorenzo Ball
17:45-18:00	Endothelial permeability in sepsis.	Daan van de Brink
18:00-18:30	<i>Discussion.</i>	
18:30	CLOSE SESSION	

DAY 2. MORNING, NOVEMBER 18, FRIDAY

8:15-10:30	SESSION 5:	Moderator: Marcus Schultz
08:15-8:30	Alveolar host response in ARDS.	Leonoor Boers
08:30-08:45	The effects of liberal versus conservative fluid therapy in different mechanical ventilation strategies on lung and distal organ damage.	Pedro Leme Silva
08:45-09:00	Pulmonary long-term sequelae in critical ill COVID patients.	Jessica González
09:00-09:15	Biomarkers in patients with ARDS supported with VV-ECMO.	Lorenzo del Sorbo
09:15-09:30	Mechanisms of lung-brain cross talk.	Luciana Mascia
09:30-09:45	The Impact of chronic liver diseases in the lung.	Raquel Herrero
09:45-10:00	<i>Discussion.</i>	
10:00-10:30	COFFEE BREAK	

10:30-13:45	SESSION 6:	Moderator: José A. Lorente
10:30-10:45	Efficacy of nebulized extracellular vesicles in E. coli induced pneumonia.	Héctor González
10:45-11:00	ADAMTS13 and trauma-induced organ failure.	Derek Kleinveld
11:00-11:15	Regional distribution of mechanical power, intensity and pulmonary inflammation in experimental lung injury.	Robert Huhle
11:15-11:30	Biomarkers of VILI, a systematic review.	Tommaso Pettenuzzo
11:30-11:45	The PaO ₂ /FiO ₂ ratio for ARDS diagnosis and stratification: physiological and clinical limits.	Tommaso Tonetti
11:45-12:00	Artificial intelligence based decision support to guide mechanical ventilation in acute respiratory failure.	Jakob Wittenstein
12:00-12:15	The future of automated ventilation.	Marcus Schultz
12:15-12:30	Alpha-1-antitrypsin: bystander or player in ARDS.	Grace Hogan
12:30-12:45	<i>Discussion.</i>	
12:45-13:45	LUNCH	

DAY 2. AFTERNOON, NOVEMBER 18, FRIDAY

13:45-16:00	SESSION 7:	Moderator: Nicole Juffermans
13:45-14:00	Personalized Medicine for ARDS.	Patricia Rocco
14:00-14:15	Resolving inflammation in ARDS: The role of counter-regulation of inflammation	Gerard Curley
14:15-14:30	Non-invasive estimation of transpulmonary pressure in spontaneously breathing patients.	Marta Sánchez Galindo
14:30-14:45	Efficacy of nebulized Extracellular Vesicles in E. coli induced pneumonia.	Héctor González
14:45-15:00	The impact of mechanical stress on lung cancer.	Inés López-Alonso
15:00-15:15	Cell therapies for ARDS - challenges and opportunities.	John Laffey
15:15-15:30	Preliminary experience with the use of Neural pressure support ventilation.	Fernando Suarez Sipmann
15:30-15:45	<i>Discussion.</i>	
16:00	CLOSE SESSION & END SYMPOSIUM	

Attention. This schedule may undergo some change.